Geron (GERN) EBITDA (2010 - 2026)
Geron (GERN) posted EBITDA of $158000.0 for Q1 2026, up 100.62% sequentially from -$25.5 million in Q4 2025, and up 100.95% YoY from $78628.1 in Q1 2025.
Geron (GERN) EBITDA (2010 - 2026) Analysis & Trends
Geron has reported EBITDA for 17 years, with the latest figure at $158000.0 in Q1 2026.
- Quarterly EBITDA rose 100.95% year-over-year to $158000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.7 million (up 61.49% YoY) and the FY2025 annual result came in at -$68.6 million, up 60.52% from the prior year.
- EBITDA grew to $158000.0 in Q1 2026 per GERN's latest filing, from -$25.5 million in the prior quarter.
- Over five years, EBITDA peaked at $158000.0 in Q1 2026 and troughed at -$69.3 million in Q2 2024.
- A 5-year average of -$33.8 million and a median of -$28.7 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2026: EBITDA sank 85.7% in 2023, then surged 100.95% in 2026.
- Over 5 years, EBITDA stood at -$42.0 million in 2022, then fell by 29.41% to -$54.3 million in 2023, then jumped by 63.07% to -$20.0 million in 2024, then retreated by 27.38% to -$25.5 million in 2025, then soared by 100.62% to $158000.0 in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $158000.0, -$25.5 million, and -$13.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Geron | 1.04 Mn | -299.81 Mn | - | -12.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.50 Mn |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | -25.54 Mn |
| Sep 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -12.45 Mn |
| Mar 31, 2025 | -16.70 Mn |
| Dec 31, 2024 | -20.05 Mn |
| Sep 30, 2024 | -28.22 Mn |
| Jun 30, 2024 | -69.33 Mn |
| Mar 31, 2024 | -56.13 Mn |
| Dec 31, 2023 | -54.29 Mn |
| Sep 30, 2023 | -47.61 Mn |
| Jun 30, 2023 | -51.95 Mn |
| Mar 31, 2023 | -40.09 Mn |
| Dec 31, 2022 | -41.95 Mn |
| Sep 30, 2022 | -39.95 Mn |
| Jun 30, 2022 | -27.98 Mn |
| Mar 31, 2022 | -28.68 Mn |
| Dec 31, 2021 | -30.98 Mn |
| Sep 30, 2021 | -25.67 Mn |